Evidence map›Paper›PMID 35567803›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2022

Nucleoside analogues for the treatment of animal trypanosomiasis.

Dorien Mabille, Kayhan Ilbeigi, Sarah Hendrickx, Marzuq A Ungogo, Fabian Hulpia, Cai Lin, Louis Maes, Harry P de Koning, Serge Van Calenbergh, Guy Caljon

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. TargetingFrontiers in microbiology · 2026
    Review
  3. Article
  4. Article
  5. Drug resistance in animal trypanosomiases: Epidemiology, mechanisms and control strategies.International journal for parasitology. Drugs and drug resistance · 2024
    Review
  6. NParasitology · 2024
    Article
  7. ACS omega · 2023
    Article
  8. Cloning and Characterization ofInternational journal of molecular sciences · 2023
    Article
  9. Pyrimidine salvage inFrontiers in cellular and infection microbiology · 2023
    Article
  10. Nucleoside Transport and Nucleobase Uptake Null Mutants inInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Dorien MabilleLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium. Electronic address: dorien.mabille@uantwerpen.be.
Kayhan IlbeigiLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium. Electronic address: kayhan.ilbeigi@uantwerpen.be.
Sarah HendrickxLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium. Electronic address: sarah.hendrickx@uantwerpen.be.
Marzuq A UngogoInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom. Electronic address: 2226184U@student.gla.ac.uk.
Fabian HulpiaLaboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium. Electronic address: FHulpia@ITS.JNJ.com.
Cai LinLaboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium. Electronic address: cai.lin@ugent.be.
Louis MaesLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium. Electronic address: louis.maes@uantwerpen.be.
Harry P de KoningInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom. Electronic address: harry.de-koning@glasgow.ac.uk.
Serge Van CalenberghLaboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium. Electronic address: serge.vancalenbergh@ugent.be.
Guy CaljonLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium. Electronic address: guy.caljon@uantwerpen.be.
University of Antwerp · BEInstitute of Infection and Immunity · CAUniversity College Ghent · BEGhent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal trypanosomiasis (AT) is a parasitic disease with high socio-economic impact. Given the limited therapeutic options and problems of toxicity and drug resistance, this study assessed redirecting our previously identified antitrypanosomal nucleosides for the treatment of AT. Promising hits were identified with excellent in vitro activity across all important animal trypanosome species. Compound 7, an inosine analogue, and our previously described lead compound, 3'-deoxytubercidin (8), showed broad spectrum anti-AT activity, metabolic stability in the target host species and absence of toxicity, but with variable efficacy ranging from limited activity to full cure in mouse models of Trypanosoma congolense and T. vivax infection. Several compounds show promise against T. evansi (surra) and T. equiperdum (dourine). Given the preferred target product profile for a broad-spectrum compound against AT, this study emphasizes the need to include T. vivax in the screening cascade given its divergent susceptibility profile and provides a basis for lead optimization towards such broad spectrum anti-AT compound.

Indexed as

TrypanosomaTrypanosoma congolenseTrypanosomiasisAnimalsDisease Models, AnimalDrug ResistanceMiceNucleosidesNucleosidesAnimal trypanosomiasisNucleoside analogues

Identifiers

PMID35567803
PMCPMC9111543
OpenAlexW4229055135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.